CA2868998A1 — Novel epoprostenol formulation and method of making thereof
Assigned to Actelion Pharmaceuticals Ltd · Expires 2007-08-16 · 19y expired
What this patent protects
This invention relates to a stable epoprostenol composition that can be combined with commercially available IV fluids and can be administered in its reconstituted and/or diluted form under ambient conditions of about 15-30°C for greater than 24 hours. The composition preferably …
USPTO Abstract
This invention relates to a stable epoprostenol composition that can be combined with commercially available IV fluids and can be administered in its reconstituted and/or diluted form under ambient conditions of about 15-30°C for greater than 24 hours. The composition preferably contains (a) epoprostenol or a salt thereof; (b) mannitol; and (c) sodium hydroxide or potassium hydroxide, wherein when the composition is reconstituted, the pH of the reconstituted solution is > 12. Methods for making the lyophilized composition are also disclosed.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.